loading...| Preferred Name |
Doripenem |
|
| Synonyms |
|
|
| Definitions |
A broad-spectrum, carbapenem antibiotic with bactericidal and beta-lactamase resistant activities. Doripenem binds to penicillin binding proteins (PBPs) located on the bacterial cell wall, particularly PBPs 2 and 3, thereby inhibiting the final transpeptidation step in the synthesis of peptidoglycan, an essential component of the bacterial cell wall. Inhibition results in a weakening and eventually lysis of the bacterial cell wall. This agent is two- to 16-fold more potent than imipenem and comparable to ertapenem and meropenem. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C65470 |
|
| Accepted_Therapeutic_Use_For |
Intraabdominal Infection, Urinary Tract Infection |
|
| CAS_Registry |
148016-81-3 |
|
| Chemical_Formula |
C15H24N4O6S2 |
|
| code |
C65470 |
|
| Contributing_Source |
FDA |
|
| definition |
A broad-spectrum, carbapenem antibiotic with bactericidal and beta-lactamase resistant activities. Doripenem binds to penicillin binding proteins (PBPs) located on the bacterial cell wall, particularly PBPs 2 and 3, thereby inhibiting the final transpeptidation step in the synthesis of peptidoglycan, an essential component of the bacterial cell wall. Inhibition results in a weakening and eventually lysis of the bacterial cell wall. This agent is two- to 16-fold more potent than imipenem and comparable to ertapenem and meropenem. |
|
| FDA_UNII_Code |
BHV525JOBH |
|
| in_subset | ||
| label |
Doripenem |
|
| Legacy Concept Name |
Doripenem |
|
| Preferred_Name |
Doripenem |
|
| prefixIRI |
NCIT:C65470 |
|
| prefLabel |
Doripenem |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C0389169 |
|
| subClassOf |